Expression And Correlation Analysis Of PFKFB3 In Vitreous And Serum Of Patients With PDR

Objectives: To discuss the possible acting mechanism of PFKFB3 in the occurrence and development of PDR by means of quantitatively measuring the levels ofphospofructokinase-2/fructose-2,6-bisphosphatase 3(PFKFB3)and vascular endothelial growth factor(VEGF)expression level in vitreous and serum of patients with proliferative diabetic retinopathy.Methods: In the study,42 patients(Group A)who were diagnosed with PDR by the Outpatient from December 5th 2015 to January 19 th 2017 and planned to accept vitrectomy in a single eye were collected,including 24 male patients and 18 female patients.The mean age was 55.43±9.29 years old.According to anti-VEGF drugs in intravitreal injection before vitrectomy,these patients were divided into non-drug-injection group(Group A1)and drug-injection group(Group A2).There were 16 patients in Group A1 with the mean age of 54.88±9.46 years old,including 9 male patients and 7 female patients,while there were 26 patients in Group A2 with the mean age of 55.77±9.35 years old,including 15 male patients and 11 female patients.In addition,20 patients who were diagnosed with full thickness macular hole(FTMH)and preretinal membrane of the macula(PRMM)and conformed to standards were selected as the control group(Group B),including 12 male patients and 8 female patients.Their mean age was 53.95±10.21 years old.The age and gender constituent ratio in each group had no statistical difference(P=0.054).All patients were operated with 25 Gplusminimally invasive vitrectomy in the ciliary body by the same professor.After operation,vitreous and serum specimens of patients in each group were collected and centrifuged for supernatant,which was cryopreserved after packaging.Enzyme-linked immunosorbent assay(ELISA)was used to detect PFKFB3 and VEGF expression level in vitreous and serum specimens.In addition,SPSS19.0 statistical software was used to do statistical analysis for data in each group.Results: PFKFB3 level(463.17±381.28pg/mL)in patients' vitreous in group A was obviously higher than the level(158.43±86.88pg/mL)(t=4.919,P<0.001)in group B.In addition,PFKFB3level(153.45±83.78pg/mL)in patients' serum in group A was apparently higher than the level(92.72±32.42pg/mL)(t=4.098,P < 0.001)in group B.PFKFB3 level(797.29±387.44pg/mL)in patients' vitreous in the group A1 was obviously higher than the level(257.56±181.49pg/mL)(t=5.230,P<0.001)in the group A2.The difference of PFKFB3 in serum between the group A1(164.72±102.57pg/mL)and group A2(146.52±71.18pg/mL)had no statistical significance(t=0.679,P=0.501).There was no correlation in PFKFB3 between patients' vitreous body and serum in the group A1,group A2 and group B(in group A1 r=0.194,P=0.47;group A2 r=0.071,P=0.731;group B r=0.254,P=0.279).VEGF level(1713.50±1386.90pg/mL)in patients' vitreous in the group A was apparently higher than the level(205.52±92.93pg/mL)(t=7.014,P<0.001)in the group B.In addition,VEGF in patients' serum in the group A level(224.98±168.08pg/mL)was obviously higher than the level(86.80±36.51pg/mL)(t=5.082,P < 0.001)in the group B.VEGF level(3399.72±510.06pg/mL)in patients' vitreous body in the group A1 was obviously higher than the level(675.82±242.57pg/mL)(t=20.014,P<0.001)in the group A2.Furthermore,VEGF level(373.40±174.23pg/mL)in patients' serum in the group A1 was also obviously higher than the level(133.65±73.10pg/mL)(t=5.228,P < 0.001)in the group A2.VEGF level in patients' vitreous body and serum in group A1,A2 and B had the positive correlation(group A1 r=0.952,P<0.001;group A2 r=0.423,P=0.031;group B r=0.776,P=0.000).3.There was the positive correlation between PFKFB3 and VEGF level in patients' vitreous body in group A1,group A2 and group B(group A1 r=0.865,P<0.001;group A2 r=0.587,P=0.002;group B r=0.807,P<0.001).Besides,there was the positive correlation between PFKFB3 and VEGF level only in group A2's serum(r=0.444,P=0.023).Group A1 and group B had no obvious correlation(group A1 r=-0.130,P=0.631;group B r=0.045,P=0.849).Conclusions: PFKFB3 level of patients with PDR's vitreous and serum was increased by comparing with the control group,showing that PFKFB3 might participate in occurrence and development of PDR.Intravitreal injection of anti-VEGF can reduce PFKFB3 level in vitreous body of patients with PDR,showing that the role of PFKFB3 in occurrence and development of PDR might be regulated by VEGF.